KKR Acquires Majority Stake in HealthCare Royalty Partners

KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add about $3 billion to the company’s assets under management.

HCRx’s team and KKR’s health care team will work together closely to offer a range of financing solutions across the biopharma sector.

KKR & Co. Inc. (NYSE:KKR) has a long history of supporting health care companies around the world. Since 2004, the company has invested over $20 billion of equity capital in the sector.

KKR & Co. Inc. (NYSE:KKR) is a global investment firm focused on alternative asset management, capital markets, and insurance solutions.

While we acknowledge the potential of KKR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 14 Best Aggressive Growth Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.